Abstract:Background Tumorigenesis is highly heterogeneous, and using clinicopathological signatures only is not enough to effectively distinguish clear cell renal cell carcinoma (ccRCC) and improve risk stratification of patients. DNA methylation (DNAm) with the stability and reversibility often occurs in the early stage of tumorigenesis. Disorders of transcription and metabolism are also an important molecular mechanisms of tumorigenesis. Therefore, it is necessary to identify effective biomarkers involved in tumorigenesis through multi-omics analysis, and these biomarkers also provide new potential therapeutic targets. Method The discovery stage involved 160 pairs of ccRCC and matched normal tissues for investigation of DNAm and biomarkers as well as 318 cases of ccRCC including clinical signatures. Correlation analysis of epigenetic, transcriptomic and metabolomic data revealed the connection and discordance among multi-omics and the deregulated functional modules. Diagnostic or prognostic biomarkers were obtained by the correlation analysis, the Least Absolute Shrinkage and Selection Operator (LASSO) and the LASSO-Cox methods. Two classifiers were established based on random forest (RF) and LASSO-Cox algorithms in training datasets. Seven independent datasets were used to evaluate robustness and universality. The molecular biological function of biomarkers were investigated using DAVID and GeneMANIA. Results Based on multi-omics analysis, the epigenetic measurements uniquely identified DNAm dysregulation of cellular mechanisms resulting in transcriptomic alterations, including cell proliferation, immune response and inflammation. Combination of the gene co-expression network and metabolic network identified 134 CpG sites (CpGs) as potential biomarkers. Based on the LASSO and RF algorithms, five CpGs were obtained to build a diagnostic classifierwith better classification performance (AUC > 99%). A eight-CpG-based prognostic classifier was obtained to improve risk stratification (hazard ratio (HR) > 4; log-rank test, p-value < 0.01). Based on independent datasets and seven additional cancers, the diagnostic and prognostic classifiers also had better robustness and stability. The molecular biological function of genes with abnormal methylation were significantly associated with glycolysis/gluconeogenesis and signal transduction. Conclusion The present study provides a comprehensive analysis of ccRCC using multi-omics data. These findings indicated that multi-omics analysis could identify some novel epigenetic factors, which were the most important causes of advanced cancer and poor clinical prognosis. Diagnostic and prognostic biomarkers were identified, which provided a promising avenue to develop effective therapies for ccRCC.

A CpG-methylation-based Assay to Predict Survival in Clear Cell Renal Cell Carcinoma

A five-gene methylation signature predicts overall survival of patients with clear cell renal cell carcinoma

A Novel DNA Methylation Signature Revealed GDF6 and RCC1 As Potential Prognostic Biomarkers Correlated with Cell Proliferation in Clear Cell Renal Cell Carcinoma

Development and Validation of an Integrative Methylation Signature and Nomogram for Predicting Survival in Clear Cell Renal Cell Carcinoma

DNA Methylation-Based Panel Predicts Survival of Patients With Clear Cell Renal Cell Carcinoma and Its Correlations With Genomic Metrics and Tumor Immune Cell Infiltration

Epigenetic signature predicts overall survival clear cell renal cell carcinoma

Comprehensive Genomic Profiling in Chinese Patients with Clear Cell Renal Cell Carcinoma.

An Effective Seven-Cpg-based Signature to Predict Survival in Renal Clear Cell Carcinoma by Integrating DNA Methylation and Gene Expression.

A novel prognostic model based on six methylation-driven genes predicts overall survival for patients with clear cell renal cell carcinoma

A prognostic signature based on genes associated with m6A/m5C/m1A/m7G modifications and its immunological characteristics in clear cell renal cell carcinoma

Identification of Differentially Methylated Genes Associated with Clear Cell Renal Cell Carcinoma and Their Prognostic Values

Identification of DNA Methylation Patterns and Biomarkers for Clear-Cell Renal Cell Carcinoma by Multi-Omics Data Analysis

Machine Learning-Based Prognosis Signature for Survival Prediction of Patients with Clear Cell Renal Cell Carcinoma

Integrated analysis of histone modification features in clear cell renal cancer for risk stratification and therapeutic prediction

Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma

Integrative Bioinformatics Analysis Demonstrates the Prognostic Value of Chromatin Accessibility Biomarkers in Clear Cell Renal Cell Carcinoma

MP78-17 PROGNOSTIC VALUE OF TISSUE BASED BIOMARKER SIGNATURE IN CLEAR CELL RENAL CELL CARCINOMA

Prediction of clear cell renal cell carcinoma prognosis based on an immunogenomic landscape analysis

Predicting response of immunotherapy and targeted therapy and prognosis characteristics for renal clear cell carcinoma based on m1A methylation regulators

A 13-Gene Risk Score System and a Nomogram Survival Model for Predicting the Prognosis of Clear Cell Renal Cell Carcinoma

Identification of a Methylation-Regulating Genes Prognostic Signature to Predict the Prognosis and Aid Immunotherapy of Clear Cell Renal Cell Carcinoma